Characteristics of all patients with PsA and PsC at first visit since 2006. Values are mean (SD) unless otherwise specified.
| Variables | PsA, n = 695 | PsC, n = 509 |
|---|---|---|
| Sex, n (%) | ||
| Female | 294 (42) | 219 (43) |
| Male | 401 (58) | 290 (57) |
| Race, n (%) | ||
| White | 601 (86) | 391 (77) |
| Other | 94 (14) | 118 (23) |
| Age at study, yrs | 49.5 (13.3) | 46.5 (13.1) |
| Age at diagnosis of psoriasis, yrs | 28.1 (14.4) | 30.3 (16.2) |
| Age at diagnosis of PsA, yrs | 37 (13.1) | — |
| Duration of psoriasis, yrs | 21.5 (13.6) | 16.2 (14) |
| Duration of PsA, yrs | 12.5 (11.1) | — |
| Alcohol, n (%) | ||
| Daily | 52 (8) | 56 (11) |
| None | 287 (42) | 148 (29) |
| Social | 351 (51) | 305 (60) |
| Smoking status, n (%) | ||
| Current | 91 (13) | 126 (25) |
| No | 370 (53) | 232 (46) |
| Past | 233 (34) | 151 (30) |
| Presence of nail lesions, n (%) | 430 (62) | 248 (49) |
| PASI score | 4.9 (7.4) | 5.6 (5.8) |
| Active SJC or TJC | 6.7 (9.2) | — |
| SJC | 1.2 (2.5) | — |
| TJC | 4.2 (7) | — |
| Damaged joint count | 7 (12.1) | — |
| Body mass index, kg/m2 | 29.3 (6.5) | 27.9 (5.7) |
| Diabetes, n (%) | 69 (10) | 35 (7) |
| Congestive heart failure, n (%) | 5 (1) | 0 (0) |
| Chronic obstructive lung disease, n (%) | 2 (0.003) | 0 (0) |
| Liver disease, n (%) | 19 (3) | 6 (1) |
| Cancer, n (%) | 27 (4) | 23 (5) |
| Use of NSAID, n (%) | 419 (60) | 18 (4) |
| Use of DMARD, n (%) | 391 (56) | 50 (10) |
| Use of biologics, n (%) | 160 (23) | 22 (4) |
| Ultraviolet light therapy, n (%) | 112 (16) | 398 (78) |
| Presence of axial disease, n (%) | 385 (55) | — |
| Steinbrocker score | 8.1 (18.6) | — |
PsA: psoriatic arthritis; PsC: psoriasis without arthritis; PASI: Psoriasis Area and Severity Index; SJC: swollen joint count; TJC: tender joint count; NSAID: nonsteroidal antiinflammatory drugs; DMARD: disease-modifying antirheumatic drugs.